公开(公告)号：EP2889309A1

公开(公告)日：2015-07-01

申请号：EP15151984.0

申请日：2007-03-02

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Minato, Nagahiro ,  Tanaka, Yoshimasa ,  Shibayama, Shiro

IPC分类号： C07K14/705 ,  A61K9/19 ,  A61K47/26 ,  A61K9/00 ,  A61K38/00

CPC分类号： C07K14/70503 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/70532 ,  Y02A50/465 ,  Y02A50/481

摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

摘要翻译： 作为药理学上调节细胞表面功能分子功能的物质，具有特异性，活性或功效等同于或优于抗体且不需要先进生产技术的物质及其应用于药物的设备已经被 要求。 本发明涉及细胞表面功能分子的细胞外结构域的多聚体，特别是PD-1或PD-L1细胞外结构域的四聚体。 此外，本发明涉及这样的四聚体作为癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及应用PD-1或PD-L1作为测试或诊断 代理人或这种疾病的研究代理人。

公开(公告)号：EP2468765A1

公开(公告)日：2012-06-27

申请号：EP12153114.9

申请日：2007-03-02

申请人： ONO Pharmaceutical Co., Ltd.

发明人： Minato, Nagahiro ,  Tanaka, Yoshimasa ,  Shibayama, Shiro

IPC分类号： C07K14/705 ,  A61K9/19 ,  A61K47/26 ,  A61K9/00

CPC分类号： C07K14/70503 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/70532 ,  Y02A50/465 ,  Y02A50/481

摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

摘要翻译： 作为药理学上调节细胞表面功能分子功能的物质，具有特异性，活性或功效等同于或优于抗体且不需要先进生产技术的物质及其应用于药物的设备已经被 要求。 本发明涉及细胞表面功能分子的细胞外结构域的多聚体，特别是PD-1或PD-L1细胞外结构域的四聚体。 此外，本发明涉及这样的四聚体作为癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及应用PD-1或PD-L1作为测试或诊断 代理人或这种疾病的研究代理人。

公开(公告)号：EP2889309B1

公开(公告)日：2017-12-27

申请号：EP15151984.0

申请日：2007-03-02

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Minato, Nagahiro ,  Tanaka, Yoshimasa ,  Shibayama, Shiro

IPC分类号： C07K14/705 ,  A61K9/19 ,  A61K47/26 ,  A61K9/00 ,  A61K38/00

CPC分类号： C07K14/70503 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/70532 ,  Y02A50/465 ,  Y02A50/481

摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

公开(公告)号：EP2468765B1

公开(公告)日：2015-04-22

申请号：EP12153114.9

申请日：2007-03-02

申请人： ONO Pharmaceutical Co., Ltd.

发明人： Minato, Nagahiro ,  Tanaka, Yoshimasa ,  Shibayama, Shiro

IPC分类号： A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/705 ,  A61K9/00

CPC分类号： C07K14/70503 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/70532 ,  Y02A50/465 ,  Y02A50/481

摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

公开(公告)号：EP2206517A1

公开(公告)日：2010-07-14

申请号：EP10161767.8

申请日：2003-07-02

申请人： Ono Pharmaceutical Co., Ltd. ,  Honjo, Tasuku

发明人： Honjo, Tasuku ,  Minato, Nagahiro ,  Iwai, Yoshiko ,  Shibayama, Shiro

IPC分类号： A61K45/00 ,  A61K38/17 ,  A61K39/395 ,  A61K31/7088 ,  A61P31/00 ,  A61P35/00 ,  A61P35/04 ,  A61P37/04 ,  C12N5/10 ,  C12Q1/02 ,  G01N33/50 ,  A61K35/14 ,  A61K33/00 ,  A61K35/00 ,  G01N33/574 ,  A01K67/027 ,  A61K31/00 ,  C07K16/28 ,  C07K14/705 ,  C07K16/46

CPC分类号： C07K16/2818 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/1774 ,  A61K38/212 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/70521 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/025 ,  G01N33/5011 ,  G01N33/574 ,  G01N2500/00 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/463 ,  Y02A50/466

摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods.
The compositions of the present invention that inhibits the function of PD-1,PD-L1, or PD-L2 are useful for cancer or infection treatment.
The compositions of the present invention comprise an anti-PD-L1 antibody.

摘要翻译： 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，通过免疫增强引起的癌症或感染治疗的组合物，用于癌症或感染的底物的筛选方法 治疗，用于筛选方法的细胞系，选择用于癌症治疗的底物的评价方法，以及用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1或PD-L2的功能的本发明的组合物可用于癌症或感染治疗。 本发明的组合物包含抗PD-L1抗体。

公开(公告)号：EP2468765A9

公开(公告)日：2014-12-31

申请号：EP12153114.9

申请日：2007-03-02

申请人： ONO Pharmaceutical Co., Ltd.

发明人： Minato, Nagahiro ,  Tanaka, Yoshimasa ,  Shibayama, Shiro

IPC分类号： A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/705 ,  A61K9/00

CPC分类号： C07K14/70503 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/00 ,  A61K47/26 ,  C07K14/70532 ,  Y02A50/465 ,  Y02A50/481

摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.

公开(公告)号：EP2243493A1

公开(公告)日：2010-10-27

申请号：EP10172772.5

申请日：2003-07-02

申请人： ONO PHARMACEUTICAL CO., LTD. ,  Honjo, Tasuku

发明人： Honjo, Tasuku ,  Minato, Nagahiro ,  Iwai, Yoshiko ,  Shibayama, Shiro

IPC分类号： A61K45/00 ,  A61K38/17 ,  A61K39/395 ,  A61K31/7088 ,  A61P31/00 ,  A61P35/00 ,  A61P35/04 ,  A61P37/04 ,  C12N5/10 ,  C12Q1/02 ,  G01N33/50 ,  A61K35/14 ,  A61K33/00 ,  A61K35/00 ,  G01N33/574 ,  A01K67/027 ,  A61K31/00 ,  C07K16/28 ,  C07K14/705 ,  C07K16/46

CPC分类号： C07K16/2818 ,  A61K9/0019 ,  A61K31/7088 ,  A61K38/1774 ,  A61K38/212 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/02 ,  A61K47/26 ,  A61K2039/505 ,  A61K2039/507 ,  C07K14/70521 ,  C07K16/18 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/025 ,  G01N33/5011 ,  G01N33/574 ,  G01N2500/00 ,  Y02A50/39 ,  Y02A50/394 ,  Y02A50/463 ,  Y02A50/466

摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods.
The compositions of the present Invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.

摘要翻译： 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，通过免疫增强引起的癌症或感染治疗的组合物，用于癌症或感染的底物的筛选方法 用于筛选方法的处理细胞系，选择用于癌症治疗的底物的评价方法，以及用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1或PD-L2的功能的本发明的组合物可用于癌症或感染治疗。